Emerson Electric
EMR
$158.57
+2.24%
Emerson Electric Co. is a global industrial technology company that provides automation software, control systems, valves, gauges, switches, and power tools to process, hybrid, and discrete manufacturing customers across energy, chemicals, life sciences, and factory automation end markets. Following the divestiture of its climate technology and consumer businesses, Emerson has repositioned itself as a more focused pure-play industrial automation leader, competing with the likes of Honeywell, ABB, Rockwell Automation, and Siemens across a broad automation hardware and software portfolio. The current investor narrative centers on whether this portfolio transformation can deliver durable mid-single-digit organic growth and margin expansion, with the Intelligent Devices segment (roughly 55% of segment revenue) and Software and Systems (roughly 33%) doing the heavy lifting while Safety and Productivity remains a smaller contributor. Recent quarterly results showing low-single-digit revenue growth alongside improving profitability have kept the debate balanced between automation-cycle optimism and valuation discipline, with sell-side analysts largely maintaining constructive but not aggressive stances.…
EMR
Emerson Electric
$158.57
Related headlines
Investment Opinion: Should I buy EMR Today?
We assign a Hold rating on Emerson Electric. The core thesis is that the company is a high-quality industrial automation franchise with improving profitability and strong cash flow, but its current valuation already reflects much of the near-term optimism, with the average analyst target of $173.50 implying only 9.6% upside. The consensus 'buy' rating and 1.9 recommendation mean suggest moderate bullishness, but the recent Deutsche Bank downgrade to Hold signals caution.
Supporting evidence includes a forward PE of 21.79x, which is reasonable if earnings grow as expected, and a net margin that expanded to 13.55% from 10.94% year-over-year. Free cash flow of $3.115 billion on a trailing basis provides ample coverage for dividends and buybacks, with a payout ratio of 51.98%. However, revenue growth of 2.93% is lackluster, and the PEG ratio of 1.78 indicates the stock is not cheap relative to its growth. The PS ratio of 4.10x is below historical averages, suggesting the market is pricing in margin expansion rather than revenue acceleration.
The biggest risks are a continued deceleration in organic growth, potential margin pressure from competition, and a high beta that could lead to outsized declines in a market downturn. The rating would upgrade to Buy if revenue growth accelerates above 5% and the forward PE remains below 22x, or downgrade to Sell if revenue growth turns negative and operating margins fall below 18%. Relative to its own history and peers, the stock appears fairly valued, with the forward PE offering a reasonable entry point only if earnings estimates are met.
Sign up to view all
EMR 12-Month Price Forecast
Emerson presents a balanced risk/reward profile. The company's strong free cash flow, improving margins, and analyst consensus buy rating support a moderately positive outlook, but decelerating revenue growth and a full valuation limit upside. The forward PE of 21.79x is reasonable if earnings grow as expected, but the PEG ratio of 1.78 suggests the stock is not cheap. We would upgrade to bullish if revenue growth accelerates above 5% and margins expand further, or downgrade to bearish if revenue growth turns negative and operating margins fall below 18%. The high beta of 1.233 warrants caution in volatile markets.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Emerson Electric's 12-month outlook, with a consensus price target around $173.68 and implied upside of +9.5% versus the current price.
Average Target
$173.68
0 analysts
Implied Upside
+9.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$104 - $205
Analyst target range
Emerson is covered by 28 analysts with a consensus recommendation of "buy" and a recommendation mean of 1.9, indicating a moderately bullish stance. The average target price is $173.50, which implies approximately 9.6% upside from the current price of $158.23, a positive but not dramatic expected return. The consensus leans bullish, supported by the buy rating and the fact that the average target sits above the current price, though the relatively modest upside suggests analysts see the stock as fairly valued with room for moderate appreciation rather than a deep discount. The target range is wide, from a low of $104.00 to a high of $205.00, a spread of $101 or roughly 64% of the current price, which signals meaningful disagreement about the company's trajectory. The high target of $205 implies roughly 29.6% upside and likely assumes accelerating automation demand, successful integration of recent portfolio changes, and multiple expansion toward the higher end of the historical range. The low target of $104 implies roughly 34.3% downside and likely prices in margin compression, weaker industrial demand, or competitive share loss. Recent institutional ratings show a mix of Equal Weight and Outperform actions, with Deutsche Bank downgrading from Buy to Hold in February 2026 and no recent upgrades, suggesting analysts are becoming more cautious even as the consensus remains constructive. The wide target spread combined with the recent downgrade activity indicates elevated uncertainty, and investors should weigh the consensus upside against the risk that the low end of the range reflects a more realistic downside scenario if industrial demand softens.
Bulls vs Bears: EMR Investment Factors
The bull case rests on margin expansion, strong free cash flow, and analyst consensus upside, while the bear case highlights decelerating revenue growth, a full valuation, and emerging analyst caution. Currently, the bear evidence is slightly stronger on growth and valuation, but the bull case is supported by improving profitability and cash generation. The single most important tension is whether Emerson can accelerate organic growth from 2.93% toward mid-single digits to justify its forward earnings expectations; if growth remains sluggish, the premium multiple is at risk, but if automation demand inflects, the stock could re-rate higher.
Bullish
- Margin expansion drives earnings growth: Net margin expanded to 13.55% in the latest quarter from 10.94% a year earlier, while operating margin held steady at 19.75%. This profitability improvement, combined with a 27.88% EBITDA margin, shows the company is converting modest revenue growth into disproportionate earnings gains.
- Strong free cash flow and capital returns: Trailing-twelve-month free cash flow is $3.115 billion, with the latest quarter generating $694 million on $779 million of operating cash flow — an 89% conversion rate. The company returned $312 million in dividends and $292 million in buybacks in the quarter, comfortably funded by cash flow.
- Analyst consensus sees upside: 28 analysts rate the stock a 'buy' with a mean recommendation of 1.9 and an average target price of $173.50, implying 9.6% upside from $158.23. The high target of $205 suggests 29.6% upside if automation demand accelerates.
- Positive technical momentum: The stock is up 21.61% over the past year and 16.50% year-to-date, outperforming SPY by 4.39 and 3.39 percentage points respectively. It sits at roughly 81% of its 52-week range, with support defended in the mid-$140s.
Bearish
- Revenue growth is decelerating: Latest quarterly revenue of $4.562 billion grew just 2.93% year-over-year, well below the double-digit growth typical of automation leaders. The sequential decline from $4.855 billion in the September 2025 quarter reflects softness in some end markets.
- Valuation is full relative to growth: The trailing PE of 32.23x and PEG ratio of 1.78 indicate the stock trades at a premium to its growth rate. The PS ratio of 4.10x is below historical levels, but the PE is above the 29.78x seen in the March 2026 quarter.
- Liquidity metrics warrant monitoring: The current ratio of 0.88 is below 1.0, meaning current liabilities exceed current assets, and debt-to-equity stands at 0.68. While free cash flow is strong, this balance sheet profile is adequate rather than fortress-like.
- Analyst caution is emerging: Deutsche Bank downgraded the stock from Buy to Hold in February 2026, and there have been no recent upgrades. The wide target range of $104 to $205 (a 64% spread) signals meaningful disagreement about the company's trajectory.
EMR Technical Analysis
Emerson is in a sustained uptrend, with the shares up 21.61% over the past year and 16.50% year-to-date, and the current price of $158.23 sits at roughly 81% of the 52-week range between a low of $122.64 and a high of $166.35. That positioning near the upper end of the range signals persistent momentum rather than deep value, though it also means the stock is within about 5% of its high and therefore vulnerable to profit-taking. The 1-year relative strength versus SPY of +4.39 percentage points confirms Emerson has outperformed the broader market, reinforcing the constructive trend structure. Short-term momentum has cooled, however: the stock is down 0.04% over the past month while SPY gained 0.69%, producing a relative strength of -0.73 percentage points, a clear deceleration from the 10.27% three-month gain and 26.18% six-month gain. This divergence between a strong 1-year trend and a flat 1-month trend suggests a consolidation or digestion phase rather than a reversal, especially since the 3-month and 6-month changes remain solidly positive. The recent price action shows the stock recovering from a September 16 low of $145.83 back to $158.23, indicating buyers are defending the mid-$140s. Key support sits at the 52-week low of $122.64, with a more immediate support zone around $145-$148 where the September pullback found buyers; resistance is the 52-week high of $166.35, and a breakout above that level would confirm trend continuation toward new highs. A breakdown below $145 would weaken the near-term structure and put the $122.64 low back in play. With a beta of 1.233, Emerson is roughly 23% more volatile than the market, meaning position sizing should account for above-market drawdown risk, and the maximum drawdown of -23.74% illustrates that this is not a low-volatility holding.
Beta
1.23
1.23x market volatility
Max Drawdown
-23.7%
Largest decline past year
52-Week Range
$123-$166
Price range past year
Annual Return
+20.9%
Cumulative gain past year
| Period | EMR Return | S&P 500 |
|---|---|---|
| 1m | +7.4% | +0.3% |
| 3m | +14.0% | +2.6% |
| 6m | +20.4% | +16.5% |
| 1y | +20.9% | +14.3% |
| ytd | +16.8% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EMR Fundamental Analysis
Emerson's revenue trajectory is modestly growing but decelerating: the most recent quarter (ending 2026-03-31) delivered $4.562 billion in revenue, up 2.93% year-over-year, following $4.346 billion in the prior quarter and $4.855 billion in the September 2025 quarter. The year-over-year growth of 2.93% is positive but well below the double-digit growth investors often associate with automation leaders, and the sequential decline from the September quarter reflects normal seasonality plus softness in some end markets. Segment data shows Intelligent Devices at $2.512 billion and Software and Systems at $1.503 billion, together representing the vast majority of revenue, while Safety and Productivity at $547 million is a smaller contributor. The growth trend implies a steady but unspectacular investment case, where multiple expansion is more likely to come from margin improvement and capital allocation than from top-line acceleration. Profitability is solid and improving: net income was $618 million in the latest quarter, up from $485 million a year earlier, with a net margin of 13.55% versus 10.94% in the prior-year quarter. Gross margin stands at 53.09%, up from 53.50% a year ago but still within a stable 52-54% band over recent quarters, while the operating margin of 19.75% is consistent with the 19-20% range seen across the last several quarters. The EBITDA margin of 27.88% and net income ratio of 13.55% indicate a business that is profitable and generating healthy cash earnings, with the year-over-year EPS improvement from $0.86 to $1.10 reflecting both revenue growth and operating leverage. The balance sheet is reasonably healthy but not fortress-like: debt-to-equity is 0.68, the current ratio is 0.88 (below 1.0, indicating current liabilities exceed current assets), and ROE is 11.31% while ROA is 6.90%. Free cash flow on a trailing-twelve-month basis is $3.115 billion, and the latest quarter generated $694 million in free cash flow on $779 million of operating cash flow, a strong 89% conversion rate. The company returned capital aggressively with $312 million in dividends and $292 million in buybacks in the quarter, funded comfortably by cash flow, though the sub-1.0 current ratio and 0.68 debt-to-equity mean liquidity is adequate rather than abundant, and the 0.88 current ratio warrants monitoring if working capital needs rise.
Quarterly Revenue
$4.9B
2026-06
Revenue YoY Growth
+7.0%
YoY Comparison
Gross Margin
54.5%
Latest Quarter
Free Cash Flow
$3.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EMR Overvalued?
Because Emerson is profitable with positive net income of $618 million in the latest quarter and trailing EPS of $0.031 (reflecting a data quirk in the key metrics feed), the PE ratio is the appropriate primary metric, and the trailing PE of 32.23x versus a forward PE of 21.79x implies the market expects meaningful earnings growth over the next twelve months. The gap between trailing and forward PE is substantial, with the forward multiple roughly 32% below the trailing multiple, signaling that consensus expects EPS to rise sharply, consistent with the analyst estimated EPS average of $9.94. This forward earnings growth expectation is the key support for the current valuation, and if it fails to materialize, the stock would look expensive on trailing numbers. Relative to the broader industrial machinery sector, Emerson's trailing PE of 32.23x and forward PE of 21.79x sit at a premium to the market but are not extreme for a high-quality automation franchise; the PS ratio of 4.10x and EV/EBITDA of 17.78x are moderate, while the PB ratio of 3.64x and PCF ratio of 23.83x reflect solid cash generation. The PEG ratio of 1.78 suggests the stock is priced at a premium to its growth rate, which is a caution flag for value-oriented investors, though the dividend yield of 1.61% and payout ratio of 51.98% indicate a shareholder-friendly capital return policy. Compared with its own history, the current PE of 32.23x is above the 29.78x seen in the March 2026 quarter and the 29.02x in September 2025, but below the 46.95x spike in mid-2024 and well below the 97.80x outlier in late 2023. The PS ratio of 4.10x is near the lower end of its historical range, which has ranged from roughly 8x to 17x in prior periods, suggesting that on a sales basis the stock is not expensive relative to its own history. The combination of an above-average PE and a below-average PS relative to history implies the market is pricing in margin expansion and earnings growth rather than revenue acceleration, and the stock's current valuation is best characterized as full but not stretched, with the forward PE providing a reasonable entry point if earnings estimates hold.
PE
32.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 16x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Emerson's financial risks are moderate but notable. The current ratio of 0.88 indicates current liabilities exceed current assets, which could strain liquidity if working capital needs rise. Debt-to-equity of 0.68 is manageable, but interest expense of $110 million in the latest quarter consumes a meaningful portion of operating income. Additionally, revenue growth of just 2.93% year-over-year means the company relies on margin expansion to drive earnings, leaving little room for operational missteps.
Market and competitive risks are elevated given the stock's premium valuation. The trailing PE of 32.23x and PEG of 1.78 suggest the market expects strong earnings growth, and any disappointment could trigger multiple compression. With a beta of 1.233, the stock is 23% more volatile than the market, amplifying drawdowns during sector rotations. Competition from Honeywell, ABB, Rockwell Automation, and Siemens in industrial automation could pressure pricing and market share, especially if end-market demand softens.
The worst-case scenario would involve a combination of slowing industrial demand, margin compression, and multiple contraction. If revenue growth turns negative and the forward PE compresses toward the low end of its historical range, the stock could fall to the analyst low target of $104, representing a 34.3% decline from the current price of $158.23. A more severe scenario could see the stock retest its 52-week low of $122.64, a 22.5% drop, if earnings estimates are cut and investor sentiment sours. Given the maximum drawdown of -23.74%, investors should be prepared for significant downside in adverse conditions.
FAQ
The key risks include: 1) Financial risk from a current ratio of 0.88 and debt-to-equity of 0.68, which could strain liquidity if working capital needs rise; 2) Competitive risk from Honeywell, ABB, Rockwell, and Siemens, which could pressure pricing and market share; 3) Macro risk due to high beta of 1.233, making the stock more volatile in downturns; and 4) Company-specific risk of decelerating revenue growth (2.93% YoY) and potential margin compression if cost inflation persists. The most severe risk is a global industrial slowdown that could cut earnings estimates and trigger a drop toward the 52-week low of $122.64.
Our 12-month forecast has three scenarios: Bull case (25% probability) targets $190-$205, assuming accelerating automation demand and margin expansion; Base case (55% probability) targets $165-$180, assuming steady 3-4% growth and stable margins; Bear case (20% probability) targets $104-$125, assuming industrial recession and margin compression. The base case is most likely, supported by analyst average target of $173.50. The key assumption is that revenue growth remains positive and margins hold near 20%. A breakout above $166.35 would confirm the bull case, while a breakdown below $145 would signal the bear case.
EMR appears fairly valued to slightly overvalued on earnings, but reasonably valued on sales. The trailing PE of 32.23x is above its recent historical average of around 29x, while the PS ratio of 4.10x is below its historical range of 8x-17x. The forward PE of 21.79x implies significant earnings growth, which may be optimistic given 2.93% revenue growth. The market is pricing in margin expansion and earnings acceleration, so any disappointment could lead to multiple compression. Relative to peers, the valuation is at a premium, reflecting its quality and automation focus.
Emerson is a good buy for long-term investors seeking exposure to industrial automation, but the current valuation offers limited upside. The stock trades at a forward PE of 21.79x, with analyst average target of $173.50 implying 9.6% upside. The company generates strong free cash flow of $3.115 billion and has improved net margins to 13.55%. However, revenue growth of 2.93% is modest, and the PEG ratio of 1.78 suggests the stock is not cheap. For those with a long-term horizon and tolerance for volatility (beta 1.233), it can be a core holding, but near-term returns may be muted.
EMR is more suitable for long-term investment (minimum 2-3 years) given its secular automation growth story, strong free cash flow, and dividend yield of 1.61%. The stock's beta of 1.233 and maximum drawdown of -23.74% make it less ideal for short-term trading, as it can be volatile. Short-term traders might find opportunities around earnings or technical levels, but the core thesis relies on multi-year trends in industrial automation and margin improvement. For long-term investors, the company's repositioning toward pure-play automation and consistent capital returns make it a solid holding, though entry point matters given the current valuation.